Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

This study found that innate lymphoid cells-type 1 (ILC1lc) can induce alopecia areata (AA) by disrupting hair follicle immune privilege and causing hair follicle dystrophy and regression in both ex vivo and in vivo settings.

This review discusses the potential of Janus kinase inhibitors as a promising new treatment for alopecia areata, suggesting they could become a first-line therapy in the future, but reports no new clinical results.

Gene expression in wool follicles changes with growth cycles, offering insights into wool and human hair growth.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this exploratory study, researchers found slightly increased levels of inflammatory markers in scalp skin affected by androgenetic alopecia, suggesting differential gene expression involved in hair cycle and keratin production.

KAP8.1 protein is crucial for hair structure and interacts with keratin 85.

In this study, the researchers used the dual-flow-RootChip to show that Arabidopsis roots can locally adapt their hair development in response to asymmetric phosphate conditions.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

The study concluded that fatty acid transport protein 4 in epidermal keratinocytes is crucial for maintaining normal skin structure, as its deficiency led to hyperkeratosis and epidermal barrier disruption in mice.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This research reported that AKR1C enzyme expression, particularly AKR1C4, in scalp sebaceous glands decreases with age, suggesting potential age-related changes in androgen metabolism affecting hair follicle health. Additionally, sulforaphane treatment increased AKR1C expression in related cell types.

In this study, topical tacrolimus 0.1% ointment applied to mice skin decreased Vegf and Igf-1 mRNA levels during late anagen but did not alter hair cycling or skin appearance compared to untreated skin.

This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.

This study found that bursts of ERK activation in the skin, termed SPREADs, are linked to increased cell division and help synchronize cell cycle progression in living mice.

This study used infrared spectral imaging to show for the first time the distribution of glypican-4 and glypican-6 in hair follicles across different growth phases, highlighting the potential of this technique for studying alopecia.

This study found that patients with alopecia areata, particularly those with severe cases, exhibit significant systemic immune dysregulation, including altered cell communication networks and epigenetic remodeling in immune cells, suggesting potential pathways for therapeutic targeting.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This study found that keratin 6hf, a type II keratin, is expressed in specific regions of mouse and human hair and suggests potential interactions with keratin 17, impacting hair development and associated disorders.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study found that the expressions of CDK inhibitors p21waf1/cip1 and p27kip1 were higher during the anagen phase compared to telogen, suggesting a role in follicular epithelial cell differentiation.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

This study found that a specific fragment of AIMP1 secreted by hair follicle stem cells can stimulate dermal papilla cells and promote hair regrowth.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.